Home | News | Directories | Calendar | Maps | Contact Us | Webmail
Perelman School of Medicine at the University of Pennsylvania Advanced Search

Janos L. Tanyi, M.D., Ph.D.

Janos L. Tanyi, M.D., Ph.D.

faculty photo
Assistant Professor of Obstetrics and Gynecology at the Hospital of the University of Pennsylvania
Department: Obstetrics and Gynecology

Contact information
University of Pennsylvania Health System,
Department of Obstetrics and Gynecology
Jordan Center for Gynecologic Cancer at Penn
Perelman Center for Advanced Medicine
3400 Civic Center Boulevard, 3 West
Philadelphia, PA 19104
Office: 215-662-3318
Fax: 215-349-5625
Education:
M.D. (Summa cum Laude)
University of Debrecen, Faculty of Medicine, Hungary , 1993.
Ph.D. (Summa cum Laude)
Semmelweis University, Faculty of Medicine, School of Clinical Sciences, Budapest, Hungary, 2008.
Permanent link
 
Perelman School of Medicine > Faculty > Search

Selected Publications

Santoiemma PP, Reyes C, Wang LP, McLane MW, Feldman MD, Tanyi JL, Powell DJ Jr: Systematic evaluation of multiple immune markers reveals prognostic factors in ovarian cancer. Gynecol Oncol 143(1):120-7, July 2016.

Jean S, Li J, Katsaros D, Wubbenhorst B, Maxwell KN, Fishbein L, McLane MW, Benedetto C, Canuto EM, Mitra N, Zhang L, Nathanson KL, Tanyi JL: Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations. Oncotarget 7(30):48577-585, May 2016.

Zhang Y, He Q, Hu Z, Feng Y, Fan L, Tang Z, Yuan J, Shan W, Li C, Hu X, Tanyi JL, Fan Y, Huang Q, Montone K, Dang CV, Zhang L: Long noncoding RNA LINP1 regulates repair of DNA double-strand breaks in triple-negative breast cancer. Nat Struct Mol Biol 23(6):522-30, Apr 2016.

Coukos G, Tanyi J, Kandalaft LE.: Opportunities in immunotherapy of ovarian cancer. Ann Oncol. Page: suppl 1):i11-i15, Apr 2016.

O’Hara M, Stashwick C, Haas AR, Tanyi JL: Mesothelin as a target for chimeric antigen receptor modified T cells as anticancer therapy. Immunotherapy 8(4):449-60, Apr 2016.

George E, Kima H, Raglanda R, Brown E, Butlerb L, Giladb O, Tanyi JL, Zhang R, Krepler C, Leed R, Morgan MA, Burger RA, Ko EM, Kim SH, Herlyn M and Simpkins F: Capitalizing on synthetic lethality in homologous recombination-deficient high-grade serous ovarian cancers with a novel ATR inhibitor. Poster on the 47th Annual Meeting of Women’s Cancer, SGO, San Diego, CA, March, 2016.

Zhong X, Zheng L, Shen J, Zhang D, Xiong M, Zhang Y, He X, Tanyi JL, Yang F, Montone KT, Chen X, Xu C, Xiang AP, Huang Q, Xu X, Zhang L: Suppression of MicroRNA 200 Family Expression by Oncogenic KRAS Activation Promotes Cell Survival and Epithelial-Mesenchymal Transition in KRAS-Driven Cancer. Mol Cell Biol 36(21):2742-54, 2016.

Tanyi JL, Haas AR, Beatty GB, Stashwick CJ, O'Hara MH, Morgan MA, Porter DL, Melenhorst JJ, Plesa G, Lacey SF, June CH: Anti-mesothelin chimeric antigen receptor T cells in patients with epithelial ovarian cancer.(suppl; abstr 5511). J Clin Oncol 34 2016.

Haas RA, Plesa G, Torigian D, Moon E, O’Hara M, Beatty G, Tanyi JL, Nelson A, Kerr N, Lacey S, Melenhorst J, Albelda SA, June C: Phase I trial of lentiviral CART-meso cells in progressive malignant pleural mesothelioma (MPM). International Mesothelioma Interest Group 2016 Annual Meeting. Birmingham, UK, May. 2016.

Pierini S, Fang C, Rafail S, Facciponte JG, Huang J, De Sanctis F, Uribe-Herranz M, Morgan MA, Tanyi JL, Facciabene A.: A Tumor Mitochondria Vaccine Protects Against Experimental Renal Cell Carcinoma. J Immunol. 195(8):: 4020-7, Oct 2015.

back to top
Last updated: 01/17/2017
The Trustees of the University of Pennsylvania